The introduction of blood biomarkers for Alzheimer’s disease is revolutionizing the biological diagnosis of this disease, enabling faster diagnosis i1
The treatments available for Alzheimer’s disease are most effective in the early stages, when it is still asymptomatic. That is why an early diagnosi1
Numerous scientific studies have identified preventable potential risk factors for the development of dementia. Fourteen of these factors and their i1
HUB Alzheimer Barcelona is a pioneering collaborative initiative rooted in a commitment to transform the future of research and provide support for p1
These findings offer a solid basis for designing clinical trials of therapies aimed at modifying the development of these neurodegenerative diseases1
Researchers at the Clínic-IDIBAPS led a study published in the Alzheimer’s & Dementia journal on the relationship between the integrity of the locus1
The centre becomes the first in Spain to use blood biomarker p-tau217, which offers a more accurate and less invasive diagnosis and marks a paradigm1
With the expansion of the Day Hospital for Neurodegenerative Diseases at the Clínic Barcelona Hospital, it will be possible to receive over 15,000 vi1
Frontotemporal dementia (FTD) and Alzheimer's disease are two different forms of dementia, which can often be confused due to sharing some of the sym1
Keeping the brain active is one of the main ways to prevent neurodegenerative diseases. There are many methods to stimulate the brain that involve bo1
